Aims and Objectives
Over the last 20 years, we assisted in an emerging crisis of antibiotic resistance for microbial pathogens throughout the world, at the very moment when increasing antimicrobial resistance has created the development of new antibiotics with novel mechanisms of action lacking. In this era the optimal use of old and eventually new antimicrobials became mandatory. The appropriate use of antimicrobials based on their pharmacological properties, including pharmacokinetic/pharmacodynamics (PK/PD) relationship, is one way to achieve clinical success. By using pharmacological information researchers, regulators and clinicians can achieve the goal of maximal therapeutic effect while reducing the risks of drug exposure-related adverse events as well as the selection of resistance. While this is now more and more recognized by Academia, Industry and Regulatory Agencies, there is presently a lack of training into these disciplines. The same applies to other areas of development of anti-infectives such as antiviral, antifungal and antiprotozoal.
This Working Group aims to promote international exchange of ideas and new research into all aspects of anti-infective pharmacology, also in collaboration with other scientific societies.
The Work Plan for the group is as follows:
- Organise a workshop on anti-infective pharmacology during the biannual ISAC Congress
- Organise occasional educational meetings
- Encourage scientific exchange with other scientific organizations
- Implement the PK/PD approach in anticancer chemotherapy
- Apply for research grants
Projects / Publications
Associate Partner in the project DRIVE-AB (Driving Reinvestment in R&D and Responsible Antibiotic Use). DRIVE-AB is a public-private consortium funded by the EU Innovative Medicines Initiative (IMI) and part of the New Drugs for Bad Bugs (ND4BB) programme. Drive Website